Connection

Co-Authors

This is a "connection" page, showing publications co-authored by XIAOJUN LIU and WILLIAM K PLUNKETT JR.
Connection Strength

2.110
  1. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer. 2012 Aug; 31(8):373-80.
    View in: PubMed
    Score: 0.441
  2. Sapacitabine for cancer. Expert Opin Investig Drugs. 2012 Apr; 21(4):541-55.
    View in: PubMed
    Score: 0.430
  3. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46.
    View in: PubMed
    Score: 0.381
  4. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer Ther. 2008 Jan; 7(1):133-42.
    View in: PubMed
    Score: 0.323
  5. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res. 2005 Aug 01; 65(15):6874-81.
    View in: PubMed
    Score: 0.273
  6. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIa inhibitor. Mol Pharmacol. 2011 Aug; 80(2):321-7.
    View in: PubMed
    Score: 0.102
  7. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Res. 2008 May 15; 68(10):3881-9.
    View in: PubMed
    Score: 0.083
  8. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol Cancer Ther. 2007 May; 6(5):1501-8.
    View in: PubMed
    Score: 0.077
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.